Form 4 for STOK Stoke Therapeutics, Inc.
Accepted 2024-03-19 00:00:00 ET · period of report 2024-03-15 · accession 0001415889-24-008683 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-19 | 2024-03-15 | STOK | Kaye Edward M. MD | CEO, Dir | M - OptEx | $0.00 | +35.5K | 80.5K | +79% | $0 |
| D | 2024-03-19 | 2024-03-19 | STOK | Kaye Edward M. MD | CEO, Dir | S - Sale+OE | $6.10 | -11.2K | 69.3K | -14% | -$68.0K |
| D | 2024-03-19 | 2024-03-15 | STOK | Kaye Edward M. MD | CEO, Dir | M - OptEx | $0.00 | -35.5K | 106.5K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-15 | M | A | 35,500 | $0.00 | 80,500 | D | — | — | |
| 2 | Common | Common Stock | 2024-03-19 | S | D | 11,150 | $6.10 | 69,350 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.94 to $6.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Restricted Stock Units | 2024-03-15 | M | D | 35,500 | $0.00 | 106,500 | D | — · — to 2027-03-15 | 35,500 Common Stock | (F3) Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. (F4) The award vested or vests as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. |